SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech News
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tnsaf who wrote (6668)10/31/2009 10:01:45 PM
From: Gary Mohilner   of 7143
 
Perhaps the FDA should reconsider its acceptance criteria. A drug that's the equal of others should be approved, rather than insisting on improvement. Of course it either needs to at minimum give at least the equal quality of life, and preferably an improved quality of life.

As I understand it, all the drugs that didn't improve on life span did provide a better quality of life for at least some patients. I also believe that some patients do live longer when their cancers are attacked by a variety of drugs, I believe in giving Oncologists as many choices as possible.

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News